Evidence map›Paper›PMID 28883730›Full record

ReviewInternational journal of nanomedicine2017

Drug delivery approaches for breast cancer.

Santosh Kumar Singh, Shriti Singh, James W Lillard, Rajesh Singh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Santosh Kumar SinghDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Shriti SinghDepartment of Kriya Sharir, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
James W LillardDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Rajesh SinghDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.

Funding

TRANSPLANTATION OF EXOSOMES FROM HYPOXIA-PRECONDITIONED ADIPOSE-DERIVED STEM CELLS PROMOTES ANGIOGENESIS IN ISCHEMIC HEARTG12MD007602 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI BOND, VINCENT C · 2012 to 2017
$18.4M
Targeted Nanotherapy for prostate cancerSC1CA193758 · NCI · MOREHOUSE SCHOOL OF MEDICINE · PI SINGH, RAJESH · 2014 to 2017
$1.4M
NCI NIH HHS SC1 CA193758NIMHD NIH HHS G12 MD007602
6 · The paper itself

Abstract

Breast cancer is one of the most common cancers affecting women worldwide. The controlled release of drugs to the precise site of the disease using a nanocarrier vehicle increases the therapeutic efficiency of the drugs. Nanotechnology-based approaches used to endorse clinical improvement from a disease also help to understand the interaction of malignant cells with their microenvironment. Receptor-based targeting is another approach for drug delivery which is undergoing clinical trials. Nanoparticles (NPs) delivery has been proven to promise high loading capacity, less toxicity, and stability of the drugs or biomolecules compared to traditional chemotherapeutic drugs. The goal of this review is to present the current problems of breast cancer therapy and discuss the NP-based targeting to overcome the hurdles of conventional drug therapy approach.

Indexed as

Antineoplastic AgentsBreast NeoplasmsDrug Delivery SystemsFemaleHumansMolecular Targeted TherapyNanoparticlesNanotechnologyAntineoplastic Agentsbreast cancerdrug delivery systemsnanoparticles

Identifiers

PMID28883730
PMCPMC5576701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.